Evidence map›Paper›PMID 34445451›Full record

ArticleInternational journal of molecular sciences2021

Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma.

Maria Rosaria Muroni, Silvia Ribback, Giovanni Sotgiu, Nils Kroeger, Laura Saderi, Andrea Angius, Paolo Cossu-Rocca, Maria Rosaria De Miglio

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Bioinformatics andBioengineered · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Maria Rosaria MuroniDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.
Silvia RibbackInstitut fuer Pathologie, Universitaetsmedizin Greifswald, Friedrich-Loeffler-Str. 23e, 17475 Greifswald, Germany.
Giovanni SotgiuDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.ORCID 0000-0002-1600-4474
Nils KroegerKlinik und Poliklinik fuer Urologie, Universitaetsmedizin Greifswald, Sauerbruchstr, 17475 Greifswald, Germany.
Laura SaderiDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.ORCID 0000-0002-5131-9367
Andrea AngiusIstituto di Ricerca Genetica e Biomedica (IRGB), CNR, Cittadella Universitaria di Cagliari, 09042 Monserrato, Italy.ORCID 0000-0003-2596-6461
Paolo Cossu-RoccaDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.
Maria Rosaria De MiglioDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.
University of Sassari · ITUniversitätsmedizin Greifswald · DEInstitute of Genetic and Biomedical Research · IT

Funding

Deutsche Forschungsgemeinschaft RI2695/1-3Fondazione di SardegnaFondo di Ateneo per la Ricerca 2020 University of sassari
6 · The paper itself

Abstract

EGFR is overexpressed in the majority of clear cell renal cell carcinomas (CCRCCs). Although EGFR deregulation was found to be of great significance in CCRCC biology, the EGFR overexpression is not associated with EGFR-targeted therapy responsiveness. Moreover, the prognostic role of EGFR expression remains controversial. In the present study, we evaluated the role played by EGFR overexpression in CCRCC and its prognostic significance associated with different immunohistochemical localization patterns. In our study, the Total Score (TS) related to membranous-cytoplasmic EGFR expression showed a significant correlation with grade, pathologic stage (pT), and Stage, Size, Grade, and Necrosis (SSIGN) score, and a negative correlation with nuclear EGFR expression. No significant correlations were shown between nuclear EGFR and clinic-pathological features. Additionally, a correlation between SGLT1 expression levels and pT was described. Multivariate analysis identifies pT and SSIGN score as independent prognostic factors for CCRCC. A significantly increased survival rate was found in the case of positive expression of nuclear EGFR and SGLT1. Based on our findings, SGLT1 and nuclear EGFR overexpression defines a subgroup of CCRCC patients with good prognosis. Membranous-cytoplasmic EGFR expression was shown to be a poor prognostic factor and could define a CCRCC subgroup with poor prognosis that should be responsive to anti-EGFR therapies.

Indexed as

AgedBiomarkers, TumorCarcinoma, Renal CellCell NucleusErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiddle AgedPrognosisSodium-Glucose Transporter 1Biomarkers, TumorEGFR protein, humanErbB ReceptorsSLC5A1 protein, humanSodium-Glucose Transporter 1clear cell renal cell carcinomamembranous-cytoplasmic EGFRnuclear EGFRprognosisSGLT1survival

Identifiers

PMID34445451
PMCPMC8395723
OpenAlexW3194654318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.